Citations

Clear

7552 citation(s) found for "Ho, Matthew".

352 Volumetric Laser Endomicroscopy Feature Discovery and Diagnostic Performance Optimization for Barrett’s Esophagus Dysplasia Using Laser-Targeted Biopsies With Histopathologic Correlation
McKinley, Matthew , Chang, Kenneth J. , Samarasena, Jason , Mashimo, Hiroshi , Smith, Michael S. , Béchard, Vincent , Vieth, Michael , Odze, Robert D. , Tearney, Gary J., Wang, Kenneth K. , Leggett, Cadman L. , Trindade, Arvind J. , Singh, Satish K.

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S207-S207

10.14309/01.ajg.0000590940.34704.29 Get It

INTRODUCTION: Volumetric laser endomicroscopy (VLE) is a high-resolution imaging modality used in Barrett’s esophagus (BE) surveillance. Established VLE scoring systems use a combination of features to guide BE dysplasia diagnosis but it remains unclear whether these features are sufficient to reach optimal VLE diagnostic performance. This study explores an exhaustive list of VLE features using one-to-one imaging to pathology correlation to develop optimal VLE diagnostic models for BE dysplasia. METHODS: In this prospective, multi-center (5 sites) study, patients with dysplastic BE underwent VLE with laser targeted regions of interest (ROIs), followed by standard surveillance endoscopy and biopsy directed to laser-marked sites. Histology was reviewed by two GI pathologists (MV, RO) who achieved a consensus diagnosis (gold-standard). ROIs were dysplastic if low-grade dysplasia (LGD), high-grade dysplasia (HGD) or intramucosal adenocarcinoma (IMC) was present. Two VLE experts (CLL, GJT) reviewed ROIs and corresponding endoscopic images to identify and define a set of VLE features associated with BE dysplasia. A multi-variable logistic regression model based on least absolute shrinkage and selection operator (LASSO) method was developed to determine the optimal diagnostic performance of these features. A decision tree model with high clinical usability also was developed to evaluate VLE diagnostic performance for real-time image interpretation. RESULTS: A total of 461 VLE ROIs with matching histology were obtained from 150 patients (Table 1). A final dataset of 55 neoplastic (LGD, 12; HGD, 24; IMC, 19) and 56 randomly selected non-dysplastic ROIs were reviewed. Twenty-eight VLE features were identified describing layering, signal intensity, surface topography, and glandular characteristics. LASSO logistic regression modeling identified 5 VLE features which when utilized optimized diagnostic performance with an area under the curve (AUC) for BE dysplasia of 0.95 (Figure 1). To improve clinical usability, a decision tree model was optimized to three levels with an AUC of 0.90 (Figure 2). CONCLUSION: This study represents the most comprehensive review of VLE features associated with BE dysplasia to date. The proposed high-performing diagnostic models suggest that VLE can be used efficiently and effectively to enhance BE surveillance by identifying ROIs for targeted biopsy. Further validation of the proposed VLE models will determine their clinical utility.
165 Effect of Bowel Preparation Volume Size in Inpatient Colonoscopy. Results of a Prospective, Randomized, Comparative Pilot Study
Hernandez, Patricia V. , Horsley‐Silva, Jennifer L. , Snyder, Diana L. , Baffy, Noemi, Atia, Mary A., Koepke, Laura, Lim, Elisabeth S. , Umar, Sarah B. , Islam, Sameer, Ramirez, Francisco C. , Buras, Matthew , Ruff, Kevin

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S101-S102

10.14309/01.ajg.0000590192.04241.e5 Get It

INTRODUCTION: Inpatient status has been shown to be a predictor of poor bowel preparation for colonoscopy since these patients are usually older, less mobile, have more medical comorbidities, and often require emergent evaluation. Our aim was to compare the efficacy of bowel preparation volume size in hospitalized patients undergoing inpatient colonoscopy. METHODS: This prospective, single blinded (endoscopist), randomized controlled trial was IRB approved and conducted as a pilot study at a Tertiary Referral Medical Center between September 2013 and March 2019. Hospitalized patients aged 18 years or older undergoing inpatient colonoscopy were assigned randomly to receive a high-volume solution (GoLYTELY®, medium-volume solution (MoviPrep®) or a low-volume Prepopik® solution. Adverse effects including unpleasant taste, nausea, and vomiting were scored through a questionnaire using a five-point scale ranging from 0 (no symptoms) to 4 (severe symptoms). Boston Bowel Prep Score (BBPS) was used to evaluate colon cleanliness. Descriptive statistics are presented as mean values ± standard deviation (SD), and P -values were calculated using Chi-Square and Kruskal-Wallis tests. RESULTS: Twenty-five colonoscopies were performed in 25 subjects. Mean age was 66.6 years (16.34) and 68% were male (Table 1). Indications for colonoscopy varied and are shown in Table 1. Total BBPS scores were higher in patients who received Prepopik®, 7.4 (1.62), than GoLYTELY® 6.6 (2.19) or MoviPrep® 6.9 (1.55), P = 0.66 (Figure 1). There was no difference in BBPS in right, transverse, or left colon scores. Regarding tolerance to preparation, 100% of the Prepopik® group reported completing the bowel preparation compared to 77.8% of the GoLYTELY® group and 66.4% of the MoviPrep® group ( P = 0.24). The Prepopik® group reported fewer side effects than GoLYTELY®/MoviPrep® groups (Table 2). CONCLUSION: In this pilot study, a low-volume colon preparation demonstrated at least equivalent quality of bowel preparation measured by BBPS in comparison with traditional higher volume regimens, with less adverse effects, and better compliance for cleansing completion. This study suggests small volume purgative may lead to better patient compliance and therefore, better bowel preparation in the inpatient setting. The lack of statistical significance is likely due to a type II error. Further more robust studies are required to confirm these findings.
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
Kumar, Shaji , Hillengaß, Jens , Liedtke, Michaela , Campagnaro, Erica , Chandler, Jason C., Cornell, Robert F. , Costello, Caitlin , Efebera, Yvonne A. , Faiman, Matthew , Garfall, Alfred L. , Godby, Kelly, Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Malek, Ehsan , Omel, James, Sborov, Douglas W. , Stockerl‐Goldstein, Keith , Tan, Carlyn , Weber, Donna, Johnson-Chilla, Alyse, Keller, Jennifer , Holmberg, Leona , Callander, Natalie S. , Baljević, Muhamed , Castillo, Jorge J. , Kang, Yubin , Landgren, Ola , Martin, Thomas G. , Raje, Noopur , Singhal, Seema , Kumar, Rashmi , Garfall, Alfred L , Campagnaro, Erica L , Stockerl-Goldstein, Keith

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 7, 2019 | Volume: 17 | Issue: 10 | Pages: 1154-1165

10.6004/jnccn.2019.0049 | PMID 31590151 Get It

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.
Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Riba, Michelle B., Donovan, Kristine A. , Andersen, Barbara L. , Braun, IIana, Breitbart, William , Brewer, Benjamin W. , Buchmann, Luke, Clark, Matthew M. , Collins, Molly, Corbett, Cheyenne , Fleishman, Stewart B., Garcia, Sofia F. , Greenberg, Donna, Handzo, Rev. George F., Hoofring, Laura, Huang, Chao‐Hui , Martin, Sara , McGuffey, Lisa, Mitchell, William M. , Morrison, Laura , Pailler, Megan E. , Parnes, Francine, Pazar, Janice P., Ralston, Laurel, Salman, Jaroslava, Shannon-Dudley, Moreen, Valentine, Alan , McMillian, Nicole R., Darlow, Susan, Garcia, Sofia F , Handzo, Rev. George F., Lally, Robin Mary , Mitchell, William, Palesh, Oxana Gronskaya

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 7, 2019 | Volume: 17 | Issue: 10 | Pages: 1229-1249

10.6004/jnccn.2019.0048 | PMID 31590149 Get It

Distress is defined in the NCCN Guidelines for Distress Management as a multifactorial, unpleasant experience of a psychologic (ie, cognitive, behavioral, emotional), social, spiritual, and/or physical nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment. Early evaluation and screening for distress leads to early and timely management of psychologic distress, which in turn improves medical management. The panel for the Distress Management Guidelines recently added a new principles section including guidance on implementation of standards of psychosocial care for patients with cancer.
Head and Neck Melanoma Incidence Trends in the Pediatric, Adolescent, and Young Adult Population of the United States and Canada, 1995-2014
Bray, Haley N, Simpson, Matthew C. , Zahirsha, Zisansha, Brinkmeier, Jennifer V. , Walen, Scott G. , Fosko, Scott W. , Osazuwa-Peters, Nosayaba, Osazuwa‐Peters, Nosayaba

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 3, 2019 | Volume: 145 | Issue: 11 | Pages: 1064

10.1001/jamaoto.2019.2769 | PMID 31580395 Get It

Ethics of Artificial Intelligence in Radiology: Summary of the Joint European and North American Multisociety Statement
Geis, J. Raymond , Brady, Adrian P. , Spencer, Jack , Ranschaert, Erik , Jaremko, Jacob L. , Langer, Steve G., Birch, Judy, Shields, William , Genderen, R. van den Hoven van , Cook, Tessa S. , Morgan, Matthew B. , Tang, An , Safdar, Nabile , Wu, Carol C. , Langer, Steve G., Kitts, Andrea Borondy , Birch, Judy, Shields, William F., Kotter, Elmar , Gichoya, Judy Wawira , Kohli, Marc

Mayo Clinic

Canadian Association of Radiologists Journal | October 1, 2019 | Volume: 70 | Issue: 4 | Pages: 329-334

10.1016/j.carj.2019.08.010 | PMID 31585825 Get It

This is a condensed summary of an international multisociety statement on ethics of artificial intelligence (AI) in radiology produced by the ACR, European Society of Radiology, RSNA, Society for Imaging Informatics in Medicine, European Society of Medical Imaging Informatics, Canadian Association of Radiologists, and American Association of Physicists in Medicine. AI has great potential to increase efficiency and accuracy throughout radiology, but it also carries inherent pitfalls and biases. Widespread use of AI-based intelligent and autonomous systems in radiology can increase the risk of systemic errors with high consequence and highlights complex ethical and societal issues. Currently, there is little experience using AI for patient care in diverse clinical settings. Extensive research is needed to understand how to best deploy AI in clinical practice. This statement highlights our consensus that ethical use of AI in radiology should promote well-being, minimize harm, and ensure that the benefits and harms are distributed among stakeholders in a just manner. We believe AI should respect human rights and freedoms, including dignity and privacy. It should be designed for maximum transparency and dependability. Ultimate responsibility and accountability for AI remains with its human designers and operators for the foreseeable future. The radiology community should start now to develop codes of ethics and practice for AI that promote any use that helps patients and the common good and should block use of radiology data and algorithms for financial gain without those two attributes.
A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition
Shee, Kevin , Wells, Jason D. , Ung, Matthew , Hampsch, Riley A. , Traphagen, Nicole A. , Liu, Stephanie C., Zeldenrust, Megan A., Wang, Liewei , Yu, Jia , Demidenko, Eugene , Kettenbach, Arminja N. , Miller, Todd W. , Cheng, Chao , Yang, Wei , Kalari, Krishna R. , Boughey, Judy C. , Cheng, Chao , Goetz, Matthew P.

Mayo Clinic

Clinical Cancer Research | September 26, 2019 | Volume: 26 | Issue: 1 | Pages: 159-170

10.1158/1078-0432.ccr-18-2213 | PMID 31558472 Get It

Abstract Purpose: We hypothesized that integrated analysis of cancer types from different lineages would reveal novel molecularly defined subgroups with unique therapeutic vulnerabilities. On the basis of the molecular similarities between subgroups of breast and ovarian cancers, we analyzed these cancers as a single cohort to test our hypothesis. Experimental Design: Identification of transcriptional subgroups of cancers and drug sensitivity analyses were performed using mined data. Cell line sensitivity to Hsp90 inhibitors (Hsp90i) was tested in vitro. The ability of a transcriptional signature to predict Hsp90i sensitivity was validated using cell lines, and cell line- and patient-derived xenograft (PDX) models. Mechanisms of Hsp90i sensitivity were uncovered using immunoblot and RNAi. Results: Transcriptomic analyses of breast and ovarian cancer cell lines uncovered two mixed subgroups comprised primarily of triple-negative breast and multiple ovarian cancer subtypes. Drug sensitivity analyses revealed that cells of one mixed subgroup are significantly more sensitive to Hsp90i compared with cells from all other cancer lineages evaluated. A gene expression classifier was generated that predicted Hsp90i sensitivity in vitro, and in cell line- and PDXs. Cells from the Hsp90i-sensitive subgroup underwent apoptosis mediated by Hsp90i-induced upregulation of the proapoptotic proteins Bim and PUMA. Conclusions: Our findings identify Hsp90i as a potential therapeutic strategy for a transcriptionally defined subgroup of ovarian and breast cancers. This study demonstrates that gene expression profiles may be useful to identify therapeutic vulnerabilities in tumor types with limited targetable genetic alterations, and to identify molecularly definable cancer subgroups that transcend lineage.
Long-Term Results of Patellar Bone-Grafting for Severe Patellar Bone Loss During Revision Total Knee Arthroplasty
Abdel, Matthew P. , Petis, Stephen M. , Taunton, Michael J. , Perry, Kevin I. , Lewallen, David G. , Hanssen, Arlen D. , Petis, Stephen , Abdel, Matthew P , Taunton, Michael J

Mayo Clinic

Journal of Bone and Joint Surgery | September 25, 2019 | Volume: 101 | Issue: 18 | Pages: 1636-1644

10.2106/jbjs.19.00519 | PMID 31567800 Get It

Background: There is no consensus on managing severe patellar bone loss after total knee arthroplasty. We previously described an initial series involving a novel technique of patellar bone-grafting with a short follow-up. The purpose of this study was to determine long-term survivorship and the radiographic and clinical results of patellar bone-grafting during revision total knee arthroplasty in a larger series with an extended follow-up. Methods: We identified 90 patients from a single institution who underwent 93 patellar bone-grafting procedures for severe patellar bone loss from 1997 to 2014. The mean age of the patients was 70 years, and 46% of patients were female. Forty-five knees (48%) underwent first-time revisions, and 19 knees (20%) had undergone a failed attempt at patellar resurfacings. Intraoperative patellar caliper thickness increased from a mean of 7 to 25 mm after patellar bone-grafting (p < 0.01). Radiographic review determined changes in patellar height, tracking, and remodeling. Knee Society scores (KSSs) were calculated. The mean follow-up was 8 years (range, 2 to 18 years). Kaplan-Meier methods determined survivorship free of any revision and any reoperation. Cox proportional hazards analysis determined predictive factors for failure. Results: Survivorship free of patellar revision was 96% at 10 years. Survivorship free of any revision was 84% at 10 years. Survivorship free of any reoperation was 78% at 10 years. Increasing patient age was the only protective factor against further patellar revision (hazard ratio, 0.95; p < 0.01). When comparing initial radiographs with final radiographs, patellar height decreased from 22 to 19 mm (p < 0.01), 80% compared with 59% of patellae articulated centrally in the trochlea (p = 0.01), and 32% compared with 77% had remodeling over the lateral femoral condyle (p < 0.01). Anterior knee pain decreased from 51% to 27% postoperatively (p = 0.01). The mean knee flexion improved from 101° to 108° (p = 0.03). The mean KSS improved from 50 to 85 points (p < 0.01). Conclusions: Reliable long-term clinical results can be expected with patellar bone-grafting for severe patellar bone loss during revision total knee arthroplasty. Pain, range of motion, and other reported outcomes improve despite radiographic changes to patellar height, tracking, and remodeling. This technique is a durable and reliable option when standard patellar resurfacing is not possible. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.